Literature DB >> 9393769

Fibronectin secretion from human peritoneal tissue induces Mr 92,000 type IV collagenase expression and invasion in ovarian cancer cell lines.

K Shibata1, F Kikkawa, A Nawa, N Suganuma, M Hamaguchi.   

Abstract

Our previous study showed that human peritoneal conditioned medium (CM) increased the matrix metalloproteinase-9 (MMP-9) secretion and invasiveness of ovarian cancer cells (NOM1). In an effort to identify this MMP-9-stimulating factor, we examined the effects of extracellular matrix components, such as type IV collagen, laminin, and fibronectin, on ovarian cancer cells. We found that fibronectin increased the MMP-9 activity of NOM1 cell CM in a concentration-dependent manner and that the peritoneal CM contained high level of fibronectin. An increase of MMP-9 activity in NOM1 cell CM by the peritoneal CM was almost completely blocked by 20 microg/ml of anti-integrin alpha5/FnR antibody and RGD polypeptides. Furthermore, after immunoprecipitation by antifibronectin antibody supernatant of the peritoneal CM did not increase MMP-9 activity in NOM1 cells. Fibronectin and the peritoneal CM also increased MMP-9 activity and expression in NOM1 cell lysate, and these effects were blocked by anti-integrin alpha5/FnR antibody. Invasiveness of NOM1 cells was enhanced by fibronectin and the peritoneal CM in a concentration-dependent manner, and anti-integrin alpha5/FnR antibody blocked these effects. These results suggested that fibronectin secreted from peritoneum increased MMP-9 activity and expression, and, in turn, invasiveness of ovarian cancer cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9393769

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

Review 1.  Integrin signaling in fibrosis and scleroderma.

Authors:  H A Gardner
Journal:  Curr Rheumatol Rep       Date:  1999-10       Impact factor: 4.592

2.  Metastatic and non-metastatic colorectal cancer (CRC) cells induce host metalloproteinase production in vivo.

Authors:  S Mc Donnell; V Chaudhry; J Mansilla-Soto; Z S Zeng; W P Shu; J G Guillem
Journal:  Clin Exp Metastasis       Date:  1999-06       Impact factor: 5.150

3.  Fibronectin activates matrix metalloproteinase-9 secretion via the MEK1-MAPK and the PI3K-Akt pathways in ovarian cancer cells.

Authors:  A A Thant; A Nawa; F Kikkawa; Y Ichigotani; Y Zhang; T T Sein; A R Amin; M Hamaguchi
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

4.  Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment.

Authors:  Nuzhat Ahmed; Clyde Riley; Greg Rice; Michael Quinn
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

Review 5.  Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.

Authors:  Hyun-Jin Choi; Guillermo N Armaiz Pena; Sunila Pradeep; Min Soon Cho; Robert L Coleman; Anil K Sood
Journal:  Cancer Metastasis Rev       Date:  2015-03       Impact factor: 9.264

6.  Regulation of matrix metalloprotease activity in malignant mesothelioma cell lines by growth factors.

Authors:  Z Liu; J Klominek
Journal:  Thorax       Date:  2003-03       Impact factor: 9.139

7.  Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target.

Authors:  Kenjiro Sawada; Anirban K Mitra; A Reza Radjabi; Vinay Bhaskar; Emily O Kistner; Maria Tretiakova; Sujatha Jagadeeswaran; Anthony Montag; Amy Becker; Hilary A Kenny; Marcus E Peter; Vanitha Ramakrishnan; S Diane Yamada; Ernst Lengyel
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

8.  SOX2 targets fibronectin 1 to promote cell migration and invasion in ovarian cancer: new molecular leads for therapeutic intervention.

Authors:  Xiaoyan Lou; Xu Han; Chengmeng Jin; Wei Tian; Wei Yu; Dong Ding; Lihua Cheng; Bingding Huang; Huawei Jiang; Biaoyang Lin
Journal:  OMICS       Date:  2013-07-29

9.  SATB1 plays an oncogenic role in esophageal cancer by up-regulation of FN1 and PDGFRB.

Authors:  Guiqin Song; Kang Liu; Xiaolin Yang; Bo Mu; Junbao Yang; Lang He; Xin Hu; Qiujiang Li; Yunxia Zhao; Xiaoming Cai; Gang Feng
Journal:  Oncotarget       Date:  2017-03-14

10.  Integrin α5β1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors.

Authors:  Florence Schaffner; Anne Marie Ray; Monique Dontenwill
Journal:  Cancers (Basel)       Date:  2013-01-15       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.